



## Reconciliation Table

### American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

### American Society of Clinical Oncology-College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

Element to Reconcile	2007 HER2 Testing Guideline Recommendation	2010 ER and PgR IHC Testing Guideline Recommendation	Reconciled Recommendation for HER2 Testing
Cold ischemic time	Time from tissue acquisition to fixation should be as short as possible; no specification of time or requirement to document	Recommends the interval be $\leq$ one hour and requires that the time between tissue removal and initiation of fixation must be recorded to document that tissue is handed from the surgical field and placed in fixative as quickly as possible.	Follow ER and PgR <sup>1</sup> Testing recommendation
Handling of specimens obtained remotely	No recommendation	Recommends that specimens be bisected through the tumor on removal and that time of removal, fixative type, and time placed in fixative must be recorded	Follow ER and PgR <sup>1</sup> recommendation
Fixation time in neutral buffered formalin	6 to 48 hours in neutral buffered formalin; less fixation time permissible for needle biopsy specimens	6 to 72 hours in neutral buffered formalin for all specimens	No changes in the recommendation listed in the 2007 HER2 guideline.
Optimal sample for testing	Resection specimens preferentially recommended for testing because of possible artifacts on core biopsy	Core needle biopsy specimens preferentially recommended for testing to avoid prolonged interval before fixation	No change in recommendation. Pathologist to use discretion in selecting sample for testing